Table 2. Demographic and clinical characteristics of 105 men who underwent fusion biopsy.
| Clinical characteristics | Median | IQR |
|---|---|---|
| Age | 65 | 59–70 |
| PSA | 7.5 | 5.0–11.2 |
| PSA density | 0.13 | 0.08–0.23 |
| Prostate volume | 58 | 39–82 |
| No. of prior TRUS biopsies | 2 | 1–3 |
| No. of cores in previous biopsy | 13 | 12–16 |
| Treatment history | No. of patients | % |
|---|---|---|
| TURP | 2 | 2 |
| 5α-reductase inhibitor | 23 | 22 |
| HT | 0 | 0 |
| Prior biopsy pathology | No. of patients | % |
|---|---|---|
| HGPIN | 12 | 11 |
| ASAP | 10 | 10 |
| Ethnicity | No. of patients | % |
|---|---|---|
| Caucasian | 79 | 75 |
| Asian | 12 | 11 |
| Hispanic | 8 | 8 |
| African American | 6 | 6 |
IQR = interquartile range; PSA = prostate-specific antigen; TRUS = transrectal ultrasound; TURP = transurethral resection of the prostate; HT = hormone therapy; HGPIN = high-grade intraepithelial neoplasia; ASAP = atypical small acinar proliferation of prostate.